Interleukin-22 (IL-22), a member of IL-10 family, plays some important roles in immune response through activation of the STAT 3 signal transduction pathway. Two types of IL-22-binding receptor have been discovered, a membrane-bound receptor and a soluble receptor, both encoded by different genes. IL-22 may be involved in inflammatory processes specifically regulated by soluble receptors. By screening a mouse genomic library for a human IL-22 binding protein homologue, we identified the mouse genomic clone of IL-22 binding protein. Its coding sequence was verified and isolated by RT-PCR. The gene encodes a protein of 230 amino acids that share 67.1% amino-acid sequence identity with human IL-22 binding protein.
Introduction
Inflammation is a key component of host defense, but extreme inflammation results in tissue destruction and, in some cases, shock and death. Anti-inflammatory cytokines or soluble cytokine receptors block this process, or at least suppress the intensity of the cascade. Therefore, a 'balance' between the effects of proinflammatory and anti-inflammatory cytokines or soluble cytokine receptors is thought to determine the outcome of disease. 1 Interleukin-10 (IL-10) is a pleiotropic cytokine that acts on many different cell types. 2 It was originally identified as an immunosuppressive cytokine, 3 but it also plays an immunostimulatory role. [4] [5] [6] Several members of the IL-10 family, including IL-19, IL-20, IL-22, MDA-7 (IL-24), and AK155 (IL-26), have only recently been discovered. IL-19 is expressed by LPS-or GM-CSF-activated monocytes. 7 Overexpression of IL-20 in transgenic mice causes neonatal lethality with skin abnormalities, including aberrant epidermal differentiation. 8 Downregulation of MDA-7 expression in primary melanomas facilitates progression to invasive and metastatic stages. 9 AK155 is induced by transformation of T lymphocytes with herpesvirus saimiri, 10 but its biological activities and receptor remain poorly understood.
IL-22 was originally identified as a gene induced by IL-9 in murine T lymphocytes. 11 The production of acutephase reactants stimulated by IL-22 in vitro and in vivo suggests its role in inflammatory response. 11, 12 IL-22 also mediates robust induction of mRNA for osteopontin (OPN) and pancreatitis-associated protein (PAP1)/Reg2, which was initially characterized as a protein elevated in pancreatitis. 13 These results indicated that IL-22 may play a role in the immune response in the pancreas. IL-22 signals through a receptor complex that contains a functional component of the IL-10 signaling molecule, IL-10R2c, and a new member of the class II cytokine receptor family, IL-22R1. 14 Its soluble receptors appear to be potent regulators of IL-22 activities. Interference with the binding of IL-22 to their membrane receptors and, thus, inhibition of cytokine signaling has been demonstrated in vitro. [15] [16] [17] In order to investigate the interaction of IL-22 and its binding protein in an animal model in the future, we isolated both genomic and cDNA clones of mouse IL-22 binding protein (mIL-22BP) by homology screening and purified the mIL-22BP recombinant protein for functional assay. We demonstrated that mIL-22BP can neutralize STAT3 activation in two hepatoma cell lines (HepG2 and H4IIE) stimulated with either human or mouse IL-22. In order to further explore novel biological functions of IL-22, we treated T cells, B cells, and monocytes with IL-22 and analyzed the result of stimulation. We found that mouse B cells produced reactive oxygen species (ROS) when stimulated with mIL-22, and that the activity was blocked by mIL-22BP.
Results
Genomic structure of the mIL-22BP gene An mIL-22BP genomic clone was isolated by homology hybridization using human cDNA clone as a probe. Part of the genomic sequence was analyzed and its coding regions were determined by a comparison of mouse genomic sequences with human cDNA sequences. The complete mouse coding region was amplified and the PCR fragment was inserted into pCR s II-TOPO s vector (Invitrogen). The cDNA sequence of mIL-22BP was compared with the mouse genomic sequences to locate the exon/intron boundaries. The translated region of mIL-22BP gene contains five exons and four introns. The exon/intron junctions conform to the GT/AT rule ( Figure 1 ). mIL-22BP is encoded by exons 2-6. Exon 1 of the human IL-22BP (hIL-22BP) was positioned B11.5 kb apart from exon 2.
17 Therefore, we may speculate that intron 1 of mouse IL-22 BP also contains more than 11 kb. The mouse genomic clone of mIL-22BP that we isolated did not contain the exon 1 untranslated region. In addition, the genomic sequence of this region was not deposited to public databases. Therefore, the boundaries of exon 1 and intron 1 could not be determined. The nucleotide sequences of mIL-22BP cDNA were submitted to the GenBank with accession number AF493604.
The amino-acid sequences of mIL-22BP and hIL-22BP are 67.1% identical. The mIL-22BP gene encodes a protein of 230 amino acids, one amino acid less than hIL-22BP. Hydropathic analysis predicts a hydrophobic signal peptide of 18 amino acids. Beginning with tryptophan (residue 19), the mature protein containing 212 amino acids has a predicted molecular mass of 24.6 kDa. Six potential N-linked glycosylation sites were detected in the amino-acid sequences, and of these six sites, only the second NNS site is identical to that of hIL-22BP. mIL-22BP has one more potential N-linked glycosylation site. The mature protein contains five cysteines, one cysteine (residue 106) more than hIL-22BP. The genomic structure of mIL-22BP in the coding region is similar to that of the hIL-22BP gene. The exon/intron boundaries in translated regions of both genes were located on the same sites ( Figure 2 ).
There is one mouse gene sequence similar to human IL-22 binding protein sequence predicted by NCBI Annotation Service (accession number XM_136951). The gene was predicted to contain four exons and three introns. The last three exons (exons 2-4) were identical to exons 3-6 of our mIL-22BP. However, the 5 0 end of the predicted exon 1 was located in the intron 2 region of our mIL-22BP (Figure 3a) . Therefore, we perform RT-PCR to verify if there is an alternative splice variant at the 5 0 end. The result demonstrated that this variant transcript was expressed in the lung tissue. This transcript was translated to a protein with different signal peptide, but retained identical amino acid of mature protein except the residue #1 at the 5 0 end (T-L) and the residue #210 at the 3 0 end (Q-H) (Figure 3b ).
Expression of mIL-22BP induced by LPS
Gene regulation of mIL-22BP in the cells was studied by reverse transcription followed by real-time PCR after LPS stimulation for various periods of time. Real-time PCR was performed with oligonucleotides specific for IL-22BP and b-actin. Analysis of hIL-22BP expression in various cell lines revealed that hIL-22BP was induced in HepG2, U937 cell lines, and monocytes upon LPS treatment for 4 h. This upregulation of mIL-22BP in monocytes by LPS could still be observed after 6 h stimulation ( Figure 4 ).
Expression and purification of recombinant proteins
Mouse and human IL-22 cDNA coding for mature proteins without signal peptides were cloned into pET32 EK/LIC vector that contained thioredoxin sequences as a fusion protein. Both mouse and human IL-22 were found to be expressed mainly in the inclusion bodies and were purified by a series of chromatography and refolding. The purified mouse and human IL-22 were treated with enterokinase (Invitrogen) to remove thioredoxin fusion protein. Pure mouse and human IL-22 showed a single band in the region of 17 kDa on the SDS-PAGE after being reduced with b-ME ( Figure 5 , lanes 1, 2). Both human and mouse IL-22 binding proteins, . Before in vitro use, all preparations of IL-22 recombinant protein were found to contain less than 2 ng/ml LPS endotoxin by the detection methods of Limulus amoebocyte lysate (LAL). Fusion protein Nus.Tag alone was also expressed in pET43A, similarly purified by chromatography, and showed a molecule of 65 kDa ( Figure 5 , lane 3). Because the hIL-22BP and mIL-22BP contained the fusion protein Nus.Tag, Nus.Tag alone was used along with hIL-22BP or mIL-22BP as a negative control in all biological function analyses to confirm that the activities observed were owing to IL-22BP and not to the fusion partner Nus.Tag.
STAT activation assay
To evaluate the interaction of IL-22 and its binding protein, rat and human hepatoma cell lines, H4IIE (ATCC HB-8065) and HepG2 (ATCC CRL-1548), were used to detect STAT3 activation stimulated by IL-22. Mouse IL-22 induced B cells to produce reactive oxygen species and was blocked by mIL-22 binding protein In a previous study, we found that IL-19 could induce monocytes to produce reactive oxygen species ROS. 18 To further evaluate interaction between mIL-22 and its binding protein to inhibit any other IL-22 activities, we used mIL-22 to treat T cells, B cells, and monocytes, and found that B cells treated with various concentrations of mIL-22 had an increase in dosage-dependent ROS production (data not shown). Human IL-22 also showed similar activity on human B cell (data not shown).
To further investigate whether this effect could be inhibited by binding protein, cells were treated with IL-22 alone or IL-22 and mIL-22BP together ( Figure 7 ). There were marked transient increases in the intracellular level of ROS in mouse B cells exposed to 300 ng/ml of mIL-22 alone. ROS production was blocked in mouse B cells exposed to both IL-22 (300 ng/ml) and mIL-22BP (600 ng/ml). Since LPS can induce ROS production, to prove that neither the induction of ROS by IL-22 nor its inhibition by IL-22BP was as result of the contamination of LPS endotoxin in the recombinant protein, the protein was heat-denatured at 1001C for 10 min, a condition under which LPS endotoxin cannot be denatured. The heat-denatured protein, IL-22, or mIL-22BP was added to B cells to test their biological activity. The results showed that the heat-denatured protein had lost most of its 
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Discussion
In this study, we cloned and characterized the mouse IL-22 binding protein gene, a homologue of human IL-22 binding protein. The sequences were highly conserved between human and mouse IL-22 binding proteins, even in the 3 0 untranslated region. There are two other alternative splice variants of hIL-22BP, long form and short form, isolated from the human placenta cDNA library and LPS-stimulated PBMCs. 16 The long form of human IL-22BP contains one extra exon, exon 4a, which is derived from intron 3 of human IL-22 BP genomic sequences. Therefore, a search for homology of mouse IL-22BP with the sequence of human exon 4a was performed in intron 3 of mouse IL-22BP genomic sequences. Intron 3 was translated into three reading frames and compared with the amino-acid sequences of human exon 4a. We could not detect any significant homology between mouse and human sequences on this region. In addition, we also performed RT-PCR to isolate similar splice variants of mIL-22BP from the tissues of heart, brain, kidney, spleen, liver, and LPS-stimulated PBMCs. We used primers located on exons 3 and 4 (for long form) and primers located on exons 4 and 6 (for short form) in PCR to amplify t hese two isoforms. We failed to find the mouse homologues of these two splice variants from these tissues. 
IL-22-induced ROS production neutralized by IL-22 binding protein Chi-Chen Wei et al
Upregulation of mIL-22BP and hIL-22BP by LPS stimulation may suggest a role associated with immune response induced by infection. Further studies will be necessary to elucidate the mechanisms regulating the expression of this cytokine and its binding protein during the infection process, and to determine potential applications of IL-22 or its binding protein in modulating immune response in vivo.
The results for STAT3 assay demonstrated that mIL-22BP neutralized not only mIL-22 activity but also hIL-22 activity. It is not surprising that these two binding proteins demonstrate 67.1% amino-acid identity and may comprise the common functional domains for IL-22 binding that shares 79% amino-acid identity in two species. 12 In addition, the other two splice variants of human IL-22 binding protein, long form and short form, showed different effects on blocking IL-22 activity. The difference may be because of the extra 32 amino acids encoded by exon 4a in long-form hIL-22BP, 16 which may mask the binding site for IL-22. This experiment was repeated five times and showed the same results each time. The difference in inhibitory effect of the three hIL-22 BPs splice variants shed some light for further study on amino-acid residues that may be involved in binding to IL-22. Expression and gene regulation of these three splice variants may also be associated with immune response and pathological outcome.
There were significant increases in the intracellular level of ROS in mouse B cells exposed to mIL-22. ROS production was blocked in mouse B cells exposed to mIL-22 preincubated with mIL-22BP. These results can also be observed in human B cells treated with hIL-22 and hIL-22BP (data not shown). These highly reactive ROS molecules are known to regulate many important cellular events, including transcription factor activation (NF-k B), 19 cellular proliferation, 20 and apoptosis. 21 IL-10 has been shown to inhibit generation of ROS in macrophages. 19 Our previous results demonstrated that IL-19, another member of the IL-10 family, induced ROS production by monocytes. 18 Therefore, the effect of the cytokines of the IL-10 family on ROS production in different targets is distinct. It is suggested that lymphocytes from individuals under oxidative stress are more prone to undergo apoptosis in vitro, 21 but no apoptosis in B cells was observed after treatment with mIL-22 (data not shown). In addition, our study of IL-19 showed that mIL-19 induced IL-6 and tumor necrosis factor-alpha (TNF-a) production in monocytes and resulted in cell apoptosis. 18 ROS generation was responsible for the induction of apoptosis of T lymphocytes obtained from HIV-1-positive patients, and ROS-dependent apoptosis was shown to be independent of cytokines such as TNFa. 22 Some experiments have illustrated that intracellular ROS mediated mouse B-cell activation, proliferation, and differentiation into plasma cells. 20 Whether or not ROS production plays an important role in mediating the functions of IL-22 awaits further comprehensive studies.
Reduction of some cytokine activity harmful to the host is accomplished by several different but highly specific strategies that involve neutralizing antibodies, soluble receptors, and receptor antagonists. Soluble cytokine receptors appear to be potent regulators of cytokine activities because they interfere with the binding of cytokines to their membrane receptors. Several major mechanisms are responsible for the generation of soluble receptors: (a) proteolytic cleavage of transmembrane receptors, (b) de novo synthesis of alternatively spliced mRNAs encoding soluble receptor molecules lacking a transmembrane domain, and (c) another secreted protein encoded by a different gene. mIL-22BP is generated by the last pathway. Therefore, gene expression and regulation of a different gene, IL-22 BP, may be very important to modulate IL-22 activity and affect its pathological outcome.
In summary, we have isolated both genomic and cDNA clones of mouse IL-22 BP. The genomic structure ÀDDCt and corrected using bactin expression and relative to untreated cell levels. HepG2, U937, and mouse monocytes (Mmono) were cultured in the absence or presence of 100 ng/ml LPS for the indicated periods of time. Total RNA was extracted and RT/real-time PCR amplification was performed with oligonucleotides specific for human and mouse IL-22BP. Figure 5 Recombinant proteins stained by Coomassie blue. These proteins were expressed in E. coli, and purified from inclusion bodies (lanes 1, 2) or cytosol (lanes 3-7) by metal chelation affinity chromatography.
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Chi-Chen Wei et al of mIL-22BP is similar to that of hIL-22BP in the coding region. We also demonstrated one alternatively spliced variant of mIL-22BP cDNA at its 5 0 end. This spliced variant does not result in the different amino-acid sequence of the mature protein. The expression level of mIL-22BP in monocytes and some cell lines was upregulated by LPS treatment. mIL-22BP blocked both human and mouse IL-22 activity on STAT 3, but two 
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of IL-22BP, the short form and the long form, had different effects on IL-22 activity. The hIL-22BP short form almost blocked human IL-22 activity and partially blocked mouse IL-22 activity in rat H4IIE cells, but not in human HepG2 cells, while the long form did not inhibit human or mouse IL-22 activity. mIL-22 induced dosage-dependent ROS production in mouse B cells, an activity that can be completely blocked by mouse binding protein.
Materials and methods
Isolation of genomic and cDNA clone of mIL-22BP A mouse genomic clone of mIL-22BP was isolated from a mouse genomic library (Strategene Inc., La Jolla, CA, USA) using hIL-22BP cDNA sequences as a hybridization probe. Genomic sequences were determined and sequences of exons were used to design primers for PCR amplification of a cDNA clone. A cDNA clone of mIL-22BP coding region was amplified by PCR from mouse heart cDNA (Clontech, Palo Alto, CA, USA) by using sense primer BP-F1 (5 0 -AAG GAA CTC TGG TTG CCA GAC AA-3 0 ) and antisense primer BP-R (5 0 -TCA TGG AAT CTG CAC ACA TCT C-3 0 ). The first round of PCR was followed by a second round, for which we used the nested sense primer BP-F2 (5 0 -ACA CTT GCA ACC ATG ATG CCT A-3 0 ) and BP-R primer. The PCR product was cloned into pCR s II-TOPO s vector (Invitrogen Corp., Carlsbad, CA, USA) by TA cloning and then sequenced.
Isolation of mIL-22BP transcripts
To evaluate the effect of LPS on mIL-22BP expressed by monocytes in vitro, mouse monocytes of 1 Â 10 6 cells were incubated at 371C with 100 ng/ml of LPS for various periods of time. Total RNA was isolated at the end of the incubation (RNAzol TM B, TEL-TEST Inc.). In all, 100 ng of total RNA was used for reverse transcription (SuperScript TM II, Invitrogen) by using oligo (dT) as primers.
Real-time PCR analysis of mIL-22BP transcripts
To amplify the transcripts of mIL-22BP, real-time PCR was performed by the LightCycler-Fast Start DNA Master SYBR Green I kit (Roche, Indianapolis, IN, USA) according to the manufacturer's instructions. A pair of primers, 5 0 -AAG GAA CTC TGG TTG CCA GAC AA-3 0 (sense primer) and 5 0 -TCA TGG AAT CTG CAC ACA TCT C-3 0 (antisense primer), specific for mIL-22BP was used in PCR. A Lightcycler (Roche, Indianapolis, IN, USA) was used for real-time PCR. cDNA was diluted 1 in 50 with nuclease-free water. A total of 2 mL of the solution was used for the Lightcycler SYBR-Green mastermix (Roche, Indianapolis, IN, USA): 0.5 mM primers, 3 mM magnesium chloride, and 2 mL Master SYBR-Green in nuclease-free water in a final volume of 20 ml. The initial denaturation phase was 5 min at 951C followed by an amplification phase including denaturation at 951C followed by annealing for 5 s at 551C and elongation at 721C for 25 s. Individual PCR products were analyzed by melting-point analysis. Samples were heated from 50 to 951C and the decline in fluorescent signals of each individual sample was assessed. Melting-point characteristics differ between individual PCR products. Using the manufacturer's software program, the fluorescence/ time-dependent generation of signals was assessed, and the melting point of each product was matched with its individual melting temperature. For internal control, a pair of primers specific for b-actin, 5 0 -GGG AAT GGG TCA GAA GGA CT-3 0 (sense primer) and 5 0 -TTT GAT GTC ACG CAC GAT TT-3 0 (antisense primer), was used to amplify b-actin transcripts. Real-time PCR was analyzed using the comparative Ct method according to the manufacturer's instructions. In brief, sample variation was corrected by subtracting b-actin Ct values from the obtained IL-22BP Ct values ( ¼ DCt). The effect of LPS was determined by subtracting the DCt value of the treated cells from the DCt value of the untreated cells. The resulting DDCt value was evaluated by expressing it as 2
ÀDDCt .
Expression of recombinant proteins in E. coli Mouse and human IL-22 cDNA coding for mature proteins without signal peptides were cloned into pET32 EK/LIC vector (Novagen Inc., Madison, WI, USA). The protein was expressed mainly in the inclusion body. Both mouse and human IL-22 were purified by metal chelation chromatography and refolding. Enterokinase was used to cleave off the fusion protein thioredoxin, and IL-22 was repurified by chromatography. mIL-22BP cDNA coding for mature protein (corresponding to amino-acid residues 19-230) was amplified by sense primer BP-T19-Hpa I (5 0 -AGC GTT AAC AGA AAT ACA ACC AGC TCG TG-3 0 ) and antisense primer BP-P230-Not I (5 0 -AGC GCG GCC GCT CAT GGA ATC TGC ACA CAT CTC-3 0 ), and then cloned into the pET43A vector (Novagen Inc., Madison, WI, USA). hIL-22BP and two splice variants, long form and short form without signal peptides, were also amplified as previously described 16 and cloned into the pET43A vector containing a fusion protein Nus.Tag (Novagen Inc., Madison, WI, USA). E. coli strain Origami-(DE3)-pLysS (Novagen Inc., Madison, WI, USA) was used as the expression host. Both mIL-22BP and hIL-22BP were expressed mainly in the cytosol fraction. Proteins were purified by metal chelation chromatography. In order to keep solubility of the receptors, both human and mouse IL-22BP were not treated with enterokinase to remove the fusion protein Nus.Tag. The purity of the recombinant proteins was evaluated by Coomassie blue staining analysis and Western blot, which was performed with anti-His antibodies. Fusion protein Nus.Tag alone was also expressed from pET43A vector and purified by chromatography. This fusion protein Nus.Tag was used as a negative control in the biological function analysis.
STAT3 assay
Rat hepatoma cells (H4IIE) or human hepatoma cells (HepG2) (2 Â 10 6 per well) were seeded in six-well flatbottomed plates the day before assay. For Western blot analysis, cells in serum-free medium were stimulated for 30 min with mouse or human IL-22 (30 ng/ml) alone or with a mixture of IL-22 and IL-22BP, both of which had been mixed and incubated for 1 h at 41C before being added to the cells. Cells treated with PBS were used as the negative control. After stimulation with IL-22, 20 ml of the cell lysates were separated on a precast NOVEX SDS-PAGE polyacrylamide gel (12%). After transfer of the protein to the nitrocellulose membrane (Hybond C; Amersham Biosciences AB, Uppsala, Sweden), the membrane was blocked in 5% nonfat dry milk, washed, and probed with rabbit polyclonal anti-phospho-STAT3 Abs (1/2000; New England Biolabs, Beverly, MA, USA) and with HRP-linked anti-rabbit Abs (1/10 000; Amersham). An ECL detection kit (Amersham) was used to analyze chemiluminescence. Anti-STAT3 Ab (1/2000; New England Biolabs) was used to confirm that an equal amount of STAT3 had been loaded into each lane.
Isolation of T cells, B cells, and monocytes from mouse spleen B cells from BALB/c mice were prepared from the spleens of 8-to 12-week-old male mice. The spleen cells were depleted of erythrocytes. Monocytes were allowed to adhere for 30 min at 371C, 5% CO 2 . The nonadherent cells were then removed by three washes with warm medium, and T cells were isolated by using mouse pan T beads (Dynabeads s ; Dynal Biotech Inc., Lake Success, NY, USA). B cells were purified from T-cell-depleted culture. The purity of T cells, B cells, and monocytes was found to be 497% by flow cytometry (FACScan; Becton Dickinson, Franklin Lakes, NJ, USA) (data not shown).
Measurement of ROS production from B cells
To evaluate the effect of mIL-22 on ROS production by T cells, B cells, or monocytes in vitro, 1 Â 10 6 of each type of cell was incubated at 371C with different concentrations of mIL-22 (from 100 to 300 ng/ml) for various times. The ROS activities were determined at the end of the incubation. Cells were collected and resuspended in 0.2 ml PBS. The CL count was measured in a completely dark chamber of the chemiluminescence analysis system. After a 100-s background level determination, 0.5 ml of 25 mM luminol in PBS (pH 7.4) was injected into the sample. The CL was monitored continuously for an additional 500 s.
